7 Einträge gefunden

1. Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison

   1. Weisel, Katja
   2. Nooka, Ajay K
   3. Terpos, Evangelos
   4. Spencer, Andrew
   5. Goldschmidt, Hartmut
   6. Dirnberger, Franziska
   7. DeCosta, Lucy

   2022 - Forschungsinformationssystem des UKE
2. Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial

   1. Hungria, Vania
   2. Beksac, Meral
   3. Weisel, Katja C
   4. Nooka, Ajay K
   5. Masszi, Tamas
   6. Spicka, Ivan
   7. Munder, Markus

   2021 - Forschungsinformationssystem des UKE
3. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

   1. Nooka, Ajay K
   2. Weisel, Katja
   3. van de Donk, Niels Wcj
   4. Routledge, David
   5. Otero, Paula Rodriguez
   6. Song, Kevin
   7. Quach, Hang

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
4. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study

   1. Lonial, Sagar
   2. Lee, Hans C
   3. Badros, Ashraf
   4. Trudel, Suzanne
   5. Nooka, Ajay K
   6. Chari, Ajai
   7. Abdallah, Al-Ola

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
5. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

   1. Lonial, Sagar
   2. Lee, Hans C
   3. Badros, Ashraf
   4. Trudel, Suzanne
   5. Nooka, Ajay K
   6. Chari, Ajai
   7. Abdallah, Al-Ola

   2020 - Forschungsinformationssystem des UKE
6. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

   1. Mateos, Maria-Victoria
   2. Spencer, Andrew
   3. Nooka, Ajay K
   4. Pour, Ludek
   5. Weisel, Katja
   6. Cavo, Michele
   7. Laubach, Jacob P

   2020 - Forschungsinformationssystem des UKE
7. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma

   1. Chari, Ajai
   2. Vogl, Dan T
   3. Gavriatopoulou, Maria
   4. Nooka, Ajay K
   5. Yee, Andrew J
   6. Huff, Carol A
   7. Moreau, Philippe

   2019 - Forschungsinformationssystem des UKE